Affiliation:
1. Department of Pharmacology, University of Essen, Essen,1
2. Department of Urology, Hospital St. Elisabeth, Straubing,2
3. IBMP-Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg,3 and
4. SmithKline Beecham Pharmaceuticals, Harlow, United Kingdom4
5. SmithKline Beecham Pharmaceuticals, Munich,5 Germany, and
Abstract
ABSTRACT
In a randomized crossover study, 16 volunteers (8 men, 8 women) received single oral doses of 320 mg of gemifloxacin and 400 mg of ofloxacin on two separate occasions in the fasting state to assess the urinary excretion and urinary bactericidal titers (UBTs) at intervals for up to 144 h. Ofloxacin showed higher concentrations in urine compared with those of gemifloxacin. The median (range) cumulative excretion of gemifloxacin was 29.7% (8.4 to 48.7%) of the parent drug administered, and median (range) cumulative excretion of ofloxacin was 84.3% (46.5 to 95.2%) of the parent drug administered. The UBTs, i.e., the highest twofold dilutions (with antibiotic-free urine as the diluent) of urine that were still bactericidal, were determined for a reference strain and nine uropathogens for which the MICs of gemifloxacin and ofloxacin were as follows:
Escherichia coli
ATCC 25922, 0.016 and 0.06 μg/ml, respectively;
Klebsiella pneumoniae
, 0.03 and 0.06 μg/ml, respectively;
Proteus mirabilis
, 0.125 and 0.125 μg/ml, respectively;
Escherichia coli
, 0.06 and 0.5 μg/ml, respectively;
Pseudomonas aeruginosa
, 1 and 4 μg/ml, respectively;
Staphylococcus aureus
, 0.008 and 0.25 μg/ml, respectively;
Enterococcus faecalis
, 0.06 and 2 μg/ml, respectively;
Staphylococcus aureus
, 0.25 and 4 μg/ml, respectively;
Enterococcus faecalis
, 0.5 and 32 μg/ml, respectively; and
Staphylococcus aureus
, 2 and 32 μg/ml, respectively. Generally, the UBTs for gram-positive uropathogens were higher for gemifloxacin than for ofloxacin and the UBTs for gram-negative uropathogens were higher for ofloxacin than for gemifloxacin. According to the UBTs, ofloxacin-resistant uropathogens (MICs, ≥4 mg/liter) should also be considered gemifloxacin resistant. Although clinical trials have shown that gemifloxacin is effective for the treatment of uncomplicated urinary tract infections, whether an oral dosage of 320 mg of gemifloxacin once daily is also adequate for the treatment of complicated urinary tract infections has yet to be confirmed.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference13 articles.
1. Multiple dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers.;Allen A.;J. Antimicrob. Chemother.,1999
2. Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers.;Allen A.;J. Antimicrob. Chemother.,1999
3. Beuth Verlag
Normenausschuβ Medizin (NAMed) im DIN (Deutsches Institut für Normung e.V.). Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (auβer Mykobakterien) gegen Chemotherapeutika. Teil 4. Bewertungsstufen der minimalen Hemmkonzentrationen. DIN 58940-4: September 1995.
1995
Beuth Verlag
Berlin Germany
4. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
5. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.;Craig W. A.;Clin. Infect. Dis.,1997
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献